KT-474

N/A

Report date: 2025/12/15 20:00:38
NME

Base Information

Drug NameKT-474
Drug Alias NameKT-474SAR444656
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionInterleukin-1 receptor-associated kinase 4 degraders
TargetsInterleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsDermatitis, AtopicHidradenitis Suppurativa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesKymera Therapeutics IncSanofi
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSanofi (China) Investment Co Ltd
Inactive CompaniesSanofiKymera Therapeutics Inc
Active IndicationsDermatitis, AtopicHidradenitis Suppurativa
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A